CERO
CERo Therapeutics Holdings, Inc.0.0850
-0.0060-6.59%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.79MP/E (TTM)
-Basic EPS (TTM)
-5.69Dividend Yield
0%Recent Filings
8-K
New $14.6M equity line
10-Q
Q3 FY2025 results
CERO Therapeutics posted a Q3 operating loss of $4.4M, slightly improved from $4.4M last year as R&D rose 34.5% to $2.4M on clinical trial ramp-up while G&A fell 24.8%. Cash burned $12.3M YTD to $2.0M quarter-end, offset by $10.5M in PIPE and ELOC inflows including Series D preferred sales; free cash flow not disclosed in the 10-Q. Dosed third AML patient in CER-1236 Phase 1 trial. Nasdaq delisted shares to OTC Pink in late October over equity shortfalls.
8-K
Nasdaq delisting suspension imminent
CERo Therapeutics' common stock faces Nasdaq suspension at open on October 31, 2025, after the Hearings Panel denied its appeal over failing the $2.5 million stockholders' equity rule. Trading shifts to less liquid OTC Markets while it appeals to the Council and eyes other exchanges. Clinical trials for CER-1236 press on amid financing uncertainty. No guarantees on funding.
8-K
CERo raises $7M via preferred stock
CERo Therapeutics Holdings entered a securities purchase agreement on October 14, 2025, to issue up to 9,750 shares of Series E convertible preferred stock for $7 million total, starting with $1.8 million at the first closing. This ranks pari passu with Series C and D preferred, convertible to common stock at $4.1625 per share, while reducing prior series conversion prices to $1.76. The deal bolsters liquidity for operations, yet demands stockholder approval by December 31, 2025, to unlock full conversions.
8-K
FDA Fast Track for CER-1236
CERo Therapeutics announced on September 5, 2025, that the FDA granted Fast Track Designation to its lead investigational compound CER-1236 for Acute Myeloid Leukemia, building on its existing Orphan Drug Designation. This milestone accelerates development for the serious condition with unmet needs, enabling more FDA interactions, potential priority review, and rolling data submissions. The ongoing Phase 1/1b trial evaluates safety and efficacy in relapsed/refractory AML patients. Yet risks persist, as actual results may differ from forward-looking expectations.
ALLO
Allogene Therapeutics, Inc.
1.54+0.07
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CLCS
Cell Source, Inc.
0.45+0.08
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
FATE
Fate Therapeutics, Inc.
1.09-0.03
FBLG
FibroBiologics, Inc.
0.24-0.02
IMRX
Immuneering Corporation
5.74-0.04
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NBTX
Nanobiotix S.A.
22.32+0.18